PYPD Stock Forecast 2025-2026
Distance to PYPD Price Targets
PYPD Price Momentum
🤔 Considering PolyPid (PYPD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest PYPD Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, PYPD has a bullish consensus with a median price target of $10.50 (ranging from $10.00 to $13.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $2.98, the median forecast implies a 252.9% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Chase Knickerbocker at Craig-Hallum, suggesting a 236.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PYPD Analyst Ratings
PYPD Price Target Range
Latest PYPD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PYPD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 26, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $11.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Nov 4, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $10.00 |
| Oct 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| Jun 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| May 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| May 1, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| Oct 23, 2023 | Barclays | Balaji Prasad | Equal-Weight | Maintains | $10.00 |
| Oct 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $16.00 |
| Sep 7, 2022 | Barclays | Balaji Prasad | Equal-Weight | Downgrade | $2.50 |
| Sep 6, 2022 | Raymond James | Elliot Wilbur | Outperform | Downgrade | $4.00 |
| Aug 11, 2022 | BMO Capital | Gary Nachman | Outperform | Maintains | $25.00 |
| Feb 11, 2022 | Raymond James | Elliot Wilbur | Strong Buy | Maintains | $17.00 |
| Sep 14, 2021 | JMP Securities | Market Outperform | Initiates | $0.00 | |
| Jul 30, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
| Aug 10, 2020 | Alliance Global Partners | Buy | Initiates | $0.00 | |
| Jul 21, 2020 | BMO Capital | Outperform | Initiates | $0.00 | |
| Jul 21, 2020 | Raymond James | Outperform | Initiates | $0.00 | |
| Jul 21, 2020 | Barclays | Overweight | Initiates | $0.00 |
PolyPid Ltd. (PYPD) Competitors
The following stocks are similar to PolyPid based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PolyPid Ltd. (PYPD) Financial Data
PolyPid Ltd. has a market capitalization of $30.32M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -1,038.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
PolyPid Ltd. (PYPD) Business Model
About PolyPid Ltd.
Develops innovative biopharmaceutical products.
The company leverages its proprietary PLEX technology platform to create products that enhance local drug delivery systems, particularly focusing on post-surgical outcomes. By providing controlled and localized release of therapeutic drugs, PolyPid generates revenue through the development and commercialization of its lead product candidates that target significant medical needs such as surgical site infections.
PolyPid operates in the biotechnology and healthcare sectors, aiming to revolutionize post-operative care and infection management. As a pioneer in biopharmaceutical research, the company attracts investor interest and contributes to advancements in healthcare solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
57
CEO
Ms. Dikla Czaczkes Akselbrad
Country
Israel
IPO Year
2020
Website
www.polypid.comPolyPid Ltd. (PYPD) Latest News & Analysis
PolyPid Ltd. has completed enrollment in the SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgery patients.
Successful enrollment in a Phase 3 trial signals potential for D-PLEX100 approval, which could lead to increased revenue and market share for PolyPid, impacting stock performance positively.
PolyPid Ltd. (Nasdaq: PYPD) will present at the 37th Annual ROTH Conference in Dana Point, California, on March 17-18, 2025, focusing on improving surgical outcomes.
PolyPid's presentation at a prominent conference may attract investor interest, signaling potential advancements in their surgical outcome technologies and influencing stock performance.
PolyPid Ltd. will host its Q4 2024 results conference call on February 12, 2025, at 8:30 AM ET, featuring key executives and analysts from various firms.
The scheduled Q4 2024 results call for PolyPid Ltd. provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
1 month agoPolyPid Ltd. received a positive recommendation to continue enrolling in the Phase 3 SHIELD II trial, expecting completion by March 2025. It raised up to $41 million to extend its cash runway.
Positive trial progress and funding extend financial stability, enhancing potential for successful product approval, which could boost stock value and investor confidence.
PolyPid Ltd. (Nasdaq: PYPD) will report Q4 and full-year 2024 financial results on February 12, 2025, before U.S. market open, followed by a conference call at 8:30 AM ET.
PolyPid's upcoming financial results and operational update could influence stock performance and investor sentiment, highlighting its progress and potential in the biopharma sector.
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1 month agoPolyPid Ltd. (Nasdaq: PYPD) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference virtually on February 11-12, 2025, focusing on surgical outcome improvements.
PolyPid's presentation at a major healthcare conference could signal upcoming developments, influencing investor sentiment and stock performance in the biotech sector.
Frequently Asked Questions About PYPD Stock
What is PolyPid Ltd.'s (PYPD) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, PolyPid Ltd. (PYPD) has a median price target of $10.50. The highest price target is $13.00 and the lowest is $10.00.
Is PYPD stock a good investment in 2025?
According to current analyst ratings, PYPD has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PYPD stock?
Wall Street analysts predict PYPD stock could reach $10.50 in the next 12 months. This represents a 252.9% increase from the current price of $2.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is PolyPid Ltd.'s business model?
The company leverages its proprietary PLEX technology platform to create products that enhance local drug delivery systems, particularly focusing on post-surgical outcomes. By providing controlled and localized release of therapeutic drugs, PolyPid generates revenue through the development and commercialization of its lead product candidates that target significant medical needs such as surgical site infections.
What is the highest forecasted price for PYPD PolyPid Ltd.?
The highest price target for PYPD is $13.00 from at , which represents a 337.0% increase from the current price of $2.98.
What is the lowest forecasted price for PYPD PolyPid Ltd.?
The lowest price target for PYPD is $10.00 from Chase Knickerbocker at Craig-Hallum, which represents a 236.1% increase from the current price of $2.98.
What is the overall PYPD consensus from analysts for PolyPid Ltd.?
The overall analyst consensus for PYPD is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.50.
How accurate are PYPD stock price projections?
Stock price projections, including those for PolyPid Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
